238 related articles for article (PubMed ID: 29403474)
1. Human NF-κB1 Haploinsufficiency and Epstein-Barr Virus-Induced Disease-Molecular Mechanisms and Consequences.
Hoeger B; Serwas NK; Boztug K
Front Immunol; 2017; 8():1978. PubMed ID: 29403474
[TBL] [Abstract][Full Text] [Related]
2. NF-κB1 Haploinsufficiency Causing Immunodeficiency and EBV-Driven Lymphoproliferation.
Boztug H; Hirschmugl T; Holter W; Lakatos K; Kager L; Trapin D; Pickl W; Förster-Waldl E; Boztug K
J Clin Immunol; 2016 Aug; 36(6):533-40. PubMed ID: 27338827
[TBL] [Abstract][Full Text] [Related]
3. Acquired and Innate Immunity Impairment and Severe Disseminated
Gonzalez-Granado LI; Ruiz-García R; Blas-Espada J; Moreno-Villares JM; Germán-Diaz M; López-Nevado M; Paz-Artal E; Toldos O; Rodriguez-Gil Y; de Inocencio J; Domínguez-Pinilla N; Allende LM
Front Immunol; 2018; 9():3148. PubMed ID: 30761159
[No Abstract] [Full Text] [Related]
4. Spectrum of Epstein-Barr virus-associated T-cell lymphoproliferative disorder in adolescents and young adults in Taiwan.
Wang RC; Chang ST; Hsieh YC; Huang WT; Hsu JD; Tseng CE; Wang MC; Hwang WS; Wang J; Chuang SS
Int J Clin Exp Pathol; 2014; 7(5):2430-7. PubMed ID: 24966953
[TBL] [Abstract][Full Text] [Related]
5. Impaired Control of Epstein-Barr Virus Infection in B-Cell Expansion with NF-κB and T-Cell Anergy Disease.
Arjunaraja S; Angelus P; Su HC; Snow AL
Front Immunol; 2018; 9():198. PubMed ID: 29472930
[No Abstract] [Full Text] [Related]
6. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
Latour S; Winter S
Front Immunol; 2018; 9():1103. PubMed ID: 29942301
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
Latour S; Fischer A
Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
[TBL] [Abstract][Full Text] [Related]
8. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
Worth AJ; Houldcroft CJ; Booth C
Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
[TBL] [Abstract][Full Text] [Related]
9. A20 (TNFAIP3) deletion in Epstein-Barr virus-associated lymphoproliferative disorders/lymphomas.
Ando M; Sato Y; Takata K; Nomoto J; Nakamura S; Ohshima K; Takeuchi T; Orita Y; Kobayashi Y; Yoshino T
PLoS One; 2013; 8(2):e56741. PubMed ID: 23418597
[TBL] [Abstract][Full Text] [Related]
10. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
Parvaneh N; Filipovich AH; Borkhardt A
Br J Haematol; 2013 Sep; 162(5):573-86. PubMed ID: 23758097
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions.
Liu WL; Lin YH; Xiao H; Xing S; Chen H; Chi PD; Zhang G
J Virol; 2014 Jun; 88(12):6660-71. PubMed ID: 24696473
[TBL] [Abstract][Full Text] [Related]
12. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency.
Bienemann K; Borkhardt A; Klapper W; Oschlies I
Histopathology; 2015 Nov; 67(5):607-16. PubMed ID: 25728094
[TBL] [Abstract][Full Text] [Related]
13. Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency.
Fliegauf M; Bryant VL; Frede N; Slade C; Woon ST; Lehnert K; Winzer S; Bulashevska A; Scerri T; Leung E; Jordan A; Keller B; de Vries E; Cao H; Yang F; Schäffer AA; Warnatz K; Browett P; Douglass J; Ameratunga RV; van der Meer JW; Grimbacher B
Am J Hum Genet; 2015 Sep; 97(3):389-403. PubMed ID: 26279205
[TBL] [Abstract][Full Text] [Related]
14. Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge.
Costagliola G; Consolini R
Clin Exp Immunol; 2021 Sep; 205(3):288-305. PubMed ID: 34008169
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus nuclear antigen 2 transactivates the long terminal repeat of human immunodeficiency virus type 1.
Scala G; Quinto I; Ruocco MR; Mallardo M; Ambrosino C; Squitieri B; Tassone P; Venuta S
J Virol; 1993 May; 67(5):2853-61. PubMed ID: 8386279
[TBL] [Abstract][Full Text] [Related]
16. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.
Salzer E; Daschkey S; Choo S; Gombert M; Santos-Valente E; Ginzel S; Schwendinger M; Haas OA; Fritsch G; Pickl WF; Förster-Waldl E; Borkhardt A; Boztug K; Bienemann K; Seidel MG
Haematologica; 2013 Mar; 98(3):473-8. PubMed ID: 22801960
[TBL] [Abstract][Full Text] [Related]
17. Advances in Understanding the Pathogenesis of Epstein-Barr Virus-Associated Lymphoproliferative Disorders.
Yang X; Nishida N; Zhao X; Kanegane H
Iran J Allergy Asthma Immunol; 2015 Oct; 14(5):462-71. PubMed ID: 26742434
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus in patients with immunodeficiency disorders.
Okano M
Biomed Pharmacother; 2001 Sep; 55(7):353-61. PubMed ID: 11669496
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr Virus Susceptibility in Activated PI3Kδ Syndrome (APDS) Immunodeficiency.
Carpier JM; Lucas CL
Front Immunol; 2017; 8():2005. PubMed ID: 29387064
[TBL] [Abstract][Full Text] [Related]
20. Age-related EBV-associated B-cell lymphoproliferative disorders and other EBV + lymphoproliferative diseases: New insights into immune escape and immunodeficiency through staining with anti-PD-L1 antibody clone SP142.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Shimada S; Eladl AE; Elsayed AA; Daroontum T; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
Pathol Int; 2020 Aug; 70(8):481-492. PubMed ID: 32367595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
